AIMS: Acute myocardial infarction (MI) leads to cardiac remodelling and development of heart failure. Insufficient myocardial capillary density after MI is considered a critical determinant of this process. MicroRNAs (miRs), negative regulators of gene expression, have emerged as important players in MI. We previously showed that miR-532-5p (miR-532) is up-regulated by the β-arrestin-biased β-adrenergic receptor antagonist (β-blocker) carvedilol, which activates protective pathways in the heart independent of G protein-mediated second messenger signalling. Here, we hypothesize that β2-adrenergic receptor/β-arrestin-responsive miR-532 confers cardioprotection against MI. METHODS AND RESULTS: Using cultured cardiac endothelial cell (CEC) and in vivo approaches, we show that CECs lacking miR-532 exhibit increased transition to a fibroblast-like phenotype via endothelial-to-mesenchymal transition (EndMT), while CECs over-expressing miR-532 display decreased EndMT. We also demonstrate that knockdown of miR-532 in mice causes abnormalities in cardiac structure and function as well as reduces CEC proliferation and cardiac vascularization after MI. Mechanistically, cardioprotection elicited by miR-532 is in part attributed to direct repression of a positive regulator of maladaptive EndMT, prss23 (a protease serine 23) in CECs. CONCLUSIONS: In conclusion, these findings reveal a pivotal role for miR-532-prss23 axis in regulating CEC function after MI, and this novel axis could be suitable for therapeutic intervention in ischemic heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Acute myocardial infarction (MI) leads to cardiac remodelling and development of heart failure. Insufficient myocardial capillary density after MI is considered a critical determinant of this process. MicroRNAs (miRs), negative regulators of gene expression, have emerged as important players in MI. We previously showed that miR-532-5p (miR-532) is up-regulated by the β-arrestin-biased β-adrenergic receptor antagonist (β-blocker) carvedilol, which activates protective pathways in the heart independent of G protein-mediated second messenger signalling. Here, we hypothesize that β2-adrenergic receptor/β-arrestin-responsive miR-532 confers cardioprotection against MI. METHODS AND RESULTS: Using cultured cardiac endothelial cell (CEC) and in vivo approaches, we show that CECs lacking miR-532 exhibit increased transition to a fibroblast-like phenotype via endothelial-to-mesenchymal transition (EndMT), while CECs over-expressing miR-532 display decreased EndMT. We also demonstrate that knockdown of miR-532 in mice causes abnormalities in cardiac structure and function as well as reduces CEC proliferation and cardiac vascularization after MI. Mechanistically, cardioprotection elicited by miR-532 is in part attributed to direct repression of a positive regulator of maladaptive EndMT, prss23 (a protease serine 23) in CECs. CONCLUSIONS: In conclusion, these findings reveal a pivotal role for miR-532-prss23 axis in regulating CEC function after MI, and this novel axis could be suitable for therapeutic intervention in ischemic heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Antti Saraste; Juha W Koskenvuo; Markku Saraste; Jussi Pärkkä; Jyri Toikka; Alexandru Naum; Heikki Ukkonen; Juhani Knuuti; Juhani Airaksinen; Jaakko Hartiala Journal: Heart Date: 2006-11-29 Impact factor: 5.994
Authors: Il-Man Kim; Timothy Ackerson; Sneha Ramakrishna; Maria Tretiakova; I-Ching Wang; Tanya V Kalin; Michael L Major; Galina A Gusarova; Helena M Yoder; Robert H Costa; Vladimir V Kalinichenko Journal: Cancer Res Date: 2006-02-15 Impact factor: 12.701
Authors: Francisco J Ortega; Josep M Mercader; José María Moreno-Navarrete; Oscar Rovira; Ester Guerra; Eduardo Esteve; Gemma Xifra; Cristina Martínez; Wifredo Ricart; Jennifer Rieusset; Sophie Rome; Monika Karczewska-Kupczewska; Marek Straczkowski; José Manuel Fernández-Real Journal: Diabetes Care Date: 2014-01-29 Impact factor: 19.112
Authors: Jian-Peng Teoh; Kyoung-Mi Park; Zuzana Broskova; Felix R Jimenez; Ahmed S Bayoumi; Krystal Archer; Huabo Su; John Johnson; Neal L Weintraub; Yaoliang Tang; Il-Man Kim Journal: Physiol Genomics Date: 2015-07-07 Impact factor: 3.107
Authors: Alessandra Castaldi; Tania Zaglia; Vittoria Di Mauro; Pierluigi Carullo; Giacomo Viggiani; Giulia Borile; Barbara Di Stefano; Gabriele Giacomo Schiattarella; Maria Giovanna Gualazzi; Leonardo Elia; Giuliano Giuseppe Stirparo; Maria Luisa Colorito; Gianluigi Pironti; Paolo Kunderfranco; Giovanni Esposito; Marie-Louise Bang; Marco Mongillo; Gianluigi Condorelli; Daniele Catalucci Journal: Circ Res Date: 2014-05-07 Impact factor: 17.367
Authors: Maryam Syed; Jana P Ball; Keisa W Mathis; Michael E Hall; Michael J Ryan; Marc E Rothenberg; Licy L Yanes Cardozo; Damian G Romero Journal: Am J Physiol Endocrinol Metab Date: 2018-08-28 Impact factor: 4.310
Authors: Jason C Kovacic; Stefanie Dimmeler; Richard P Harvey; Toren Finkel; Elena Aikawa; Guido Krenning; Andrew H Baker Journal: J Am Coll Cardiol Date: 2019-01-22 Impact factor: 24.094